Does Wegovy only suppress appetite, or is there more going on?

Step 1, what GLP-1 receptors actually do when semaglutide arrives

GLP-1 is a hormone your gut releases naturally after eating. Its job is to signal to the pancreas, the stomach and the brain that food has arrived. Semaglutide (the active ingredient in Wegovy) is a synthetic version that binds to GLP-1 receptors far more persistently than the hormone your body makes, because it is designed to resist the enzymes that would normally break it down within minutes.

The result is a sustained signal across several systems at once. The pancreas responds by releasing insulin in proportion to blood sugar. The stomach slows down how quickly it empties its contents into the small intestine. And the hypothalamus, the part of the brain that governs hunger, receives a prolonged message that the body is in a fed state. Our full Wegovy overview covers the licensed indications and what the clinical programme found across different patient groups.

So when people say Wegovy "suppresses appetite", they are describing the end result of a process that starts in the gut and reaches the brain, not a single switch being flipped. That distinction matters practically, because it explains why the medicine affects not just how hungry you feel but how quickly hunger returns after a meal, and if you are wondering how soon Wegovy suppresses appetite after you start taking it, the answer depends on which part of that chain you are measuring.

Step 2, the gastric-emptying effect and why it changes how meals feel

Slowed gastric emptying might sound like a technical footnote, but it has a real, noticeable effect on daily life. Food sits in the stomach longer, which sustains the physical sensation of fullness and delays the hormonal signals that would otherwise prompt your next meal. People on semaglutide often find they cannot finish portions they used to manage easily, or that they stop feeling hungry between meals in a way they have not experienced before.

This is also the mechanism behind some of the most common side effects. Nausea, a feeling of fullness that tips into discomfort, and slower digestion can all follow from the stomach holding onto food longer than it used to. The wider picture of how Wegovy affects appetite explores why these effects tend to be most noticeable in the early weeks and after each dose increase. They often settle as the body adjusts, though that timeline varies between people.

If you have been worried that side effects mean the medicine is not working properly, you are not alone, it is one of the questions our prescribers hear most often. The discomfort and the effectiveness come from the same underlying mechanism.

Step 3, what happens in the brain, beyond hunger

This is the part that surprises many people. GLP-1 receptors are not only in the gut. They are also present in areas of the brain involved in reward, motivation and the anticipation of food, including regions associated with cravings for highly palatable foods like sugar and alcohol. Semaglutide reaches some of these areas, and clinical observations suggest it can reduce the pull of food cravings independently of whether someone is physically hungry.

Patients sometimes describe this as food becoming less interesting, or noticing that the urge to eat in response to stress or boredom has quietened. That is meaningfully different from simply feeling full. A closer look at whether Wegovy is only an appetite suppressant goes further into the brain-based evidence if you want to read more on this.

Understanding this helps set realistic expectations too. What to eat on Wegovy becomes a more useful question once you know that the medicine reshapes food preferences as well as portion tolerance, protein and fibre matter more, not less, when appetite falls sharply.

The STEP 1 trial, published in the New England Journal of Medicine, found an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, alongside lifestyle intervention, a result that reflects all of these mechanisms working together, not appetite suppression alone.

Step 4, what this means for how treatment is structured

Because the mechanisms are multiple and the side-effect profile is dose-related, Wegovy is titrated gradually. A prescriber starts you on a low dose and increases it in steps, typically every four weeks, watching for tolerability at each level. The target maintenance dose under the current licensed schedule is 2.4mg weekly, though the MHRA has also approved a higher 7.2mg dose for adults with a BMI of 30 or above, approved by the MHRA in April 2026, with a single-dose pen now available. Which dose a prescriber moves toward depends on how a person responds clinically, there is no one-size answer.

For anyone weighing up the private cost of treatment, a transparent breakdown of Wegovy pricing in the UK sets out what typical private prescriptions include and what is often left out. And if the NHS route is relevant to you, our treatment overview explains how private and NHS pathways compare at a practical level.

Wegovy is a prescription-only medicine. A prescriber assesses your full health picture before treatment starts, and the same clinical review happens before each repeat supply. If you have questions about whether the mechanisms above apply to your situation, speaking to a qualified prescriber is the only way to get an answer that is specific to you. Speak to our prescribers through a free consultation, same-day review, no waiting list.